The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, eLife (June 26, 2020).

The study, titled, “3,6'-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation,” may be found here (https://elifesciences.org/articles/54726).